a look at fundamental COVID-19 developments over the past week

we're in greater form all over the second Thanksgiving holiday of the pandemic now that vaccines, boosters and speedy assessments are widely attainable.

but as temperatures drop and family unit and friends huddle indoors, the number of new infections is up once more.

here’s a look at major tendencies involving COVID-19 and a glance forward.

Numbers expanding again

In Georgia, after months of growth, the number of COVID-19 infections has been rising once again over the past couple of weeks. For the previous seven days, the normal of newly confirmed and suspected circumstances became 1,145 in accordance with state records posted Wednesday. That’s up 18% over the last two weeks.

And whereas the number of cases remains pretty low in Georgia, specifically when compared to other materials of the nation, the uptick is a being concerned sign heading into the busy holiday season.

an increase in case numbers may also be the first signal of rising transmission in a group. Hospitalizations and deaths are inclined to lag case counts by several days, as it takes time for americans to develop into contaminated with the virus after which become unwell ample to need medical care.

The variety of Georgians hospitalized for COVID-19 is still relatively low and dropped to 838 Wednesday, down from greater than 6,000 in early September.

lines for safety screening stretched during the domestic terminal atrium and down hallways at Hartsfield-Jackson foreign Airport on Wednesday, the day before Thanksgiving.

credit score: Kelly Yamanouchi

credit score: Kelly Yamanouchi

ExploreCORONAVIRUS IN GEORGIA/finished COVERAGEEmory-developed drug seeks good enough

An antiviral capsule invented by means of Emory researchers might quickly turn into the first drug of its kind within the U.S. to treat COVID-19, a potentially essential step in efforts to battle the pandemic.

On Tuesday, The meals and Drug Administration is scheduled to believe an emergency use authorization request for the experimental drug called molnupiravir, which turned into developed by Emory’s Drug Innovation Ventures and licensed to Merck pharmaceutical enterprise via its accomplice Ridgeback Biotherapeutics last 12 months.

ExploreEmory-developed COVID drug seeks FDA approval

Merck pointed out the capsule reduced hospitalizations and deaths via half in americans these days infected with the coronavirus in a medical trial when it turned into given within five days of when indicators all started.

The FDA will scrutinize business records on the safety and effectiveness of the drug earlier than making a choice.